CD19 and non-Hodgkin lymphoma: Although the excitement of using CD19 CAR-T cells was initially significant in patients with R/R NHL, the (progression-free survival) PFS rate ranges between 30- 50%, and for those who do not receive CAR-T treatment, the results were unpleasant.